Posted by Michael Wonder on 04 Apr 2022
FDA approves Nobelpharma's Hyftor (sirolimus 0.2% topical gel)
4 April 2022 - Hyftor is the first topical treatment approved by the FDA for facial angiofibroma in individuals with tuberous sclerosis complex 6 years and older.
Nobelpharma America today announced that the U.S. FDA has approved Hyftor (sirolimus 0.2% topical gel) as the first topical treatment indicated for facial angiofibroma associated with tuberous sclerosis complex in adults and children six years of age or older.
